Fulgent Genetics, Inc.

Fulgent Genetics operates as a clinical diagnostics and therapeutic development company serving physicians, patients, hospitals, insurers, and corporate clients across the United States and internationally. The company provides molecular diagnostic testing, genetic testing, and anatomic pathology laboratory services spanning gastrointestinal, dermatologic, urologic, breast, neuro, and hematologic pathology. Additionally, Fulgent Genetics offers oncology testing services and sequencing capabilities focused on hereditary cancer and reproductive health assessment.

The company's therapeutic development segment pursues drug candidate development for cancer treatment, utilizing a nanoencapsulation and targeted therapy platform designed to optimize the therapeutic window and pharmacokinetic characteristics of oncology compounds. Fulgent Genetics also operates its picture genetics platform, which combines gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information systems to enable customers to identify health markers within personal genetic sequences.

Based in El Monte, California, Fulgent Genetics maintains a workforce of approximately 1,313 full-time employees. The company was founded in 2011, incorporated in Delaware, and changed its name from Fulgent Diagnostics to Fulgent Genetics in August 2016. It is listed on Nasdaq with a market capitalization of approximately $0.7 billion.